- Home
- LIN vs ABBV Comparison
LIN vs ABBV Comparison
Compare LIN & ABBV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LIN | ABBV |
|---|---|---|
| Founded | 1879 | 2012 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 234.1B | 358.5B |
| IPO Year | 2017 | 2012 |
Fundamental Metrics
Financial Performance| Metric | LIN | ABBV |
|---|---|---|
| Price | $480.21 | $254.78 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 8 | 18 |
| Target Price | ★ $543.13 | $253.71 |
| AVG Volume (30 Days) | 2.0M | ★ 3.6M |
| Earning Date | 05-01-2026 | 04-29-2026 |
| Dividend Yield | 1.27% | ★ 3.39% |
| EPS Growth | ★ 7.27 | N/A |
| EPS | ★ 8.13 | 2.42 |
| Revenue | $33,986,000,000.00 | ★ $61,160,000,000.00 |
| Revenue This Year | $5.90 | $11.87 |
| Revenue Next Year | $5.10 | $8.12 |
| P/E Ratio | ★ $58.34 | $103.49 |
| Revenue Growth | 2.97 | ★ 8.57 |
| 52 Week Low | $387.78 | $190.75 |
| 52 Week High | $548.20 | $267.47 |
Technical Indicators
Market Signals| Indicator | LIN | ABBV |
|---|---|---|
| Relative Strength Index (RSI) | 37.10 | 57.74 |
| Support Level | $471.43 | $242.14 |
| Resistance Level | $506.63 | $261.30 |
| Average True Range (ATR) | 8.37 | 5.53 |
| MACD | -1.12 | -0.30 |
| Stochastic Oscillator | 25.40 | 73.57 |
Price Performance
Historical ComparisonAbout LIN Linde plc
Linde is the largest industrial gas supplier in the world, with operations in over 100 countries. The firm's main products are atmospheric gases (including oxygen, nitrogen, and argon) and process gases (including hydrogen, carbon dioxide, and helium), as well as equipment used in industrial gas production. Linde serves a wide variety of end markets, including chemicals, manufacturing, healthcare, and steelmaking. Linde generated approximately $34 billion in revenue in 2025.
About ABBV AbbVie Inc.
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio.